Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted ...

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Researchers have found that a pair of drugs can not only slow down Alzheimer’s disease but actually reverse it and restore memory in mice.

The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

Shares of PTC Therapeutics climbed after the company said federal regulators approved its treatment for elevated levels of a certain amino acid in the blood. The stock was up 11%, at $49.08, midday ...

The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

Sepiapterin is a PAH activator that reduces blood Phe levels by increasing the intracellular concentrations of tetrahydrobiopterin and protecting against PAH enzyme misfolding.

But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI ...

It's since become popular in the United States. Haddow, with the American Kratom Association, said more than 24 million ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

The FDA just approved a new natural color additive for use in food, named gardenia (genipin) blue. This color is derived from ...